Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market To See Incredible Growth By 2026

Methicillin-Resistant Staphylococcus Aureus (MRSA) is a type of staphylococcus aureus, which became resistant to methicillin, amoxicillin, penicillin, oxacillin, and other such commonly used antibiotics. Staphylococcus aureus harbors on the skin and nasal passage of about one third of the world population, which comprises around 33%, as per Centers for Disease Control and Prevention (CDC) review 2015. MRSA can be classified into two types, based on mode of infection – Hospital Associated MRSA Infection (HA-MRSA) or community-associated MRSA infections (CA-MRSA). Staphylococcus aureus leads to skin infections such as boils, pimples, impetigo, abscesses or certain life threatening conditions such as septicemia (blood poisoning), pneumonia (lung infection), osteomyelitis (bone infection), endocarditis (heart valve infection), urinary tract infection, and septic bursitis (formation of small fluid-filled sacs under the skin). Growth of the methicillin-resistant staphylococcus aureus (MRSA) drug market is driven by increasing product pipeline and increasing adoption of organic and inorganic strategies by key market players. Click To Read More On Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market.

Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market – Driver

Increasing number of pipeline products for the treatment of methicillin resistance staphylococcus aureus infection is expected to fuel growth of the Methicillin-Resistant Staphylococcus Aureus (MRSA) drug market during the forecast period. For instance, in 2014, Cubist Pharmaceuticals Inc., received US FDA approval for its new antibiotic, Sivextro, available in both the forms – injection as well as oral, to treat skin infection caused by gram positive bacteria including MRSA. Moreover, new route of administration are experimented by market players to treat MRSA infection. For instance, in 2018, Destiny Pharma received investigational new drug application from FDA for its new candidate, XF-73, a dicationic porphyrin molecule based nasal gel, to combat with post-surgical infections of methicillin-resistant Staphylococcus aureus (MRSA). These increasing number of product approvals is expected to aid in growth of the MRSA drugs market over the forecast period.

Moreover, funding programs by healthcare organization will also propel drug discovery and development program, in turn leading to growth of the MRSA drug market. For instance, in 2017, Cystic Fibrosis Foundation Therapeutics (CFFT)—a non-profit drug discovery and development arm of Cystic Fibrosis Foundation—awarded US$ 5 million to Savara Inc., a clinical-stage specialty pharmaceutical company, for the development of AeroVanc, vancomycin hydrochloride inhalation powder, intended to treat MRSA lung infection in individual with cystic fibrosis.

Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market – Competitor

Key market player in methicillin-resistant staphylococcus aureus (MRSA) drugs market are Basilea Pharmaceutica Ltd., Cubist Pharmaceuticals Inc., Melinta Therapeutics, Inc., Theravance Biopharma, Allergan, Merck & Co., Xellia Pharmaceuticals ApS (owned by Novo Holdings A/S), King Pharmaceuticals Inc. (a wholly owned subsidiary of Pfizer), and PF Prism C.V. Players in the market are focusing inorganic growth strategies in order to enhance its market share and remain competitive in the market.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1538

Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market - Regional Analysis

Geographically, global methicillin-resistant staphylococcus aureus (MRSA) drugs market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America holds dominant position in methicillin-resistant staphylococcus aureus (MRSA) drugs market, owing to increasing research and development studies by key market players to come up with new drug. For instance, in 2016, Allergan plc received US FDA approval for Dalance in injectable form for acute bacterial skin and skin structure infections (ABSSSI) caused by methicillin-resistant Staphylococcus aureus (MRSA). Asia Pacific is expected to witness fastest growth over the forecast period. This is due to larger patient pool and increasing market player’s strategies to expand their geographical reach in this region.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Submitting intelligent market insights of the market situations for healthcare services